Last reviewed · How we verify
DMAB Discontinuation and Switching
This is a clinical study protocol examining the safety and efficacy of discontinuing or switching from denosumab (DMAB), a RANKL inhibitor used for bone loss prevention.
This is a clinical study protocol examining the safety and efficacy of discontinuing or switching from denosumab (DMAB), a RANKL inhibitor used for bone loss prevention. Used for Osteoporosis in postmenopausal women, Bone loss in patients with cancer receiving hormone-deprivation therapy, Giant cell tumor of bone.
At a glance
| Generic name | DMAB Discontinuation and Switching |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | RANKL inhibitor (monoclonal antibody) |
| Target | RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) |
| Modality | Small molecule |
| Therapeutic area | Bone Metabolism / Osteoporosis |
| Phase | FDA-approved |
Mechanism of action
Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), thereby reducing osteoclast formation and bone resorption. This study investigates what happens when patients discontinue DMAB therapy or switch to alternative treatments, monitoring for rebound bone loss and fracture risk. The research aims to establish optimal management strategies for patients who cannot continue or tolerate denosumab therapy.
Approved indications
- Osteoporosis in postmenopausal women
- Bone loss in patients with cancer receiving hormone-deprivation therapy
- Giant cell tumor of bone
Common side effects
- Hypocalcemia
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Rebound bone loss after discontinuation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: